ERBB2 and non-small cell lung carcinoma: Interest in targeting HER2 alterations in NSCLC made a comeback thanks to ADCs.82 T-DM1 was evaluated in HER2-overexpressing NSCLC with unsatisfying results, especially in patients with HER2 IHC 2+,83 while promising results were seen in patients with HER2-mutant NSCLC (ORR: 44%), irrespectively of the mutation subtypes and HER2-protein expression levels.84